Periinterventionelle Antikoagulation bei der Vorhofflimmerablation

Abstract

Ablation of atrial fibrillation is associated with a significant risk of thromboembolism and bleeding. Whereas continuous application of vitamin K antagonists seem to be feasible, the increasing use of direct oral anticoagulants (DOAKs) in patients with atrial fibrillation moves this topic in a novel focus for interventional electrophysiologists. The article describes current use of oral anticoagulants for atrial fibrillation ablation.

• Literatur

• 1 Camm AJ, Lip GY, De Caterina R et al. Guidelines ESCCfP. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012; 33: 2719-2747
• 2 January CT, Wann LS, Alpert JS et al. American College of Cardiology/American Heart Association Task Force on Practice G. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2014; 64: e1-e76
• 3 Di Biase L, Burkhardt JD, Santangeli P et al. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the Role of Coumadin in Preventing Thromboembolism in Atrial Fibrillation (AF) Patients Undergoing Catheter Ablation (COMPARE) randomized trial. Circulation 2014; 129: 2638-2644
• 4 Wu S, Yang YM, Zhu J et al. Meta-Analysis of Efficacy and Safety of New Oral Anticoagulants Compared With Uninterrupted Vitamin K Antagonists in Patients Undergoing Catheter Ablation for Atrial Fibrillation. Am J Cardiol 2016; 117: 926-934
• 5 Cappato R, Marchlinski FE, Hohnloser SH et al. Investigators V-A. Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation. Eur Heart J 2015; 36: 1805-1811